CoChat

Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies

The DOI matches its Crossref record; 154 of the 161 references it cites were found in a registry or an index.

Abstract

BACKGROUND Evidence of comparative benefits of long-acting injectable antipsychotics (LAIs) versus oral antipsychotics for schizophrenia has been inconsistent across study designs. The aim of this study was to evaluate the comparative benefits of LAIs versus oral antipsychotics in three study designs to inform clinical decision making. METHODS We did a comprehensive systematic review and meta-analysis comparing LAIs versus oral antipsychotics for schizophrenia covering three study designs: randomised controlled trials (RCTs), cohort studies, and pre-post studies. Our literature search was without language restrictions, in MEDLINE and PubMed, the Cochrane Library, Scopus, and Embase, for studies published from database inception up to a last search on March 13, 2020. We also searched for unpublished studies and ClinicalTrials.gov. We included studies lasting at least 6 months that targeted adults with schizophrenia and related disorders (>80% of participants). Studies on penfluridol (neither an LAI or daily oral antipsychotic), case reports, and case series with fewer than 20 patients were excluded. Two investigators independently extracted study-level data and resolved disagreement by consensus, or via a third investigator. Study authors were contacted to obtain additional information as needed. For our primary outcome we meta-analysed the risk ratio (RR) for hospitalisation or relapse with LAIs versus oral antipsychotics by a random-effects model, with hospitalisation used p…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2215-0366(21)00039-0

Cites

154 of 154 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 154 references

Research works printed but not linked: 6

  1. Kamijima, 2009, Comparison study between risperidone long-acting injectable and risperidone tablets in patients with schizophrenia, Jpn J Clin Psychopharmacol, 12, 1199
  2. Kaneno, 1991, A double-blind comparison study on the efficacy and safety of fluphenazine decanoate (SQ10,733) and oral haloperidol in the treatment of schizophrenic patients, Clin Eval, 19, 15
  3. Li, 1996, The effect of haloperidol decanoate on negative and positive symptoms of schizophrenia, Chinese Journal of Nervous and Mental Diseases, 22, 9
  4. Potapov, 2008, Response, remission and relapse during the long-term treatment of schizophrenia patients with long-acting injectable risperidone versus olanzapine, Int J Neuropsychopharmacol, 11, 158
  5. Bellido, 2008, Depot antipsychotics in outpatients with schizophrenia improved compliance and reduced the incidence of relapses, Methods Find Exp Clin Pharmacol, 30, 137
  6. Calabresi, 1983, The long-term pharmacological treatment of schizophrenic patients: comparing effects resulting from daily administered neuroleptics and “long acting”, Riv Sper Freniatr Med Leg Alien Ment, 107, 1205

Cited by

See all 369

Metadata

Authors
Kishimoto, T., Hagi, K., Kurokawa, S., Kane, J. M., & Correll, C. U.
Affiliations
  • Northwell Health (US)
  • Sumitomo Dainippon Pharma (Japan) (JP)
  • Keio University (JP)
Corresponding author
Kishimoto, Taishiro
Venue
The Lancet Psychiatry
Publisher
Elsevier BV
Published
2021-05
Volume
8
Issue
5
Pages
387-404
ISSN
2215-0366 (ISSN-L)
OpenAlex
W3154038235
Cited by
369
References
161
Citations by year
2026: 69 · 2025: 68 · 2024: 72 · 2023: 74 · 2022: 64 · 2021: 22
FWCI
10.41
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Takeda Pharmaceutical Company
  • Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Psychology › Clinical Psychology › Psychiatric care and mental health services
  • Social Sciences › Psychology › Clinical Psychology › Family Caregiving in Mental Illness
Keywords
long-acting injectable antipsychotics, oral antipsychotics, schizophrenia, maintenance therapy, relapse, hospitalization, study design comparison, cohort studies, before-after study, antipsychotic efficacy and safety, quality of life, cognitive function, medication adherence, relapse prevention, antipsychotic switching
MeSH terms
Administration, Oral, Delayed-Action Preparations, Humans, Injections, Schizophrenia, Antipsychotic Agents, Cohort Studies, Randomized Controlled Trials as Topic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. https://app.cochat.ai/papers/10.1016/s2215-0366(21)00039-0
The paper
Kishimoto, T., Hagi, K., Kurokawa, S., Kane, J. M., & Correll, C. U. (2021). Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(21)00039-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.